On November 3, 2023, in connection with the reduction in headcount described, Sorrento Therapeutics, Inc. terminated the employment of Elizabeth Czerepak as its Executive Vice President and Chief Financial Officer effective immediately.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.013 USD | +6,400.00% | +8.33% | -89.47% |
Apr. 10 | Sorrento Therapeutics, Inc. Emerged from Bankruptcy | CI |
Mar. 15 | Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs | MT |
1st Jan change | Capi. | |
---|---|---|
-89.47% | 7.07M | |
+9.58% | 115B | |
+12.41% | 107B | |
-2.59% | 21.6B | |
-12.38% | 22.31B | |
-5.29% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- SRNE Stock
- News Sorrento Therapeutics, Inc.
- Sorrento Therapeutics, Inc. Announces Termination of the Employment of Elizabeth Czerepak as Its Executive Vice President